🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

325 results for “Disc” Clear

  1. Olumiant 2 mg film-coated tablets, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    phase 2 small molecule active

    1 trial

  2. PEGINTERFERON ALFA-2A , TIL cells, Zirconium Zr 89 crefmirlimab berdoxam

    Disc Medicine

    Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  3. PYRIMETHAMINE, LENALIDOMIDE, PANOBINOSTAT

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  4. Padcev 30 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Padcev 20 mg powder for concentrate for solution for infusion

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  5. Placebo: Normal Saline - Solution for injection, Daxdilimab

    Elan Pharma International

    Primary Discoid Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  6. Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie

    Disc Medicine

    MDS with excess blasts, MDS/AML or AML patients

    phase 2 small molecule active

    1 trial

  7. Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg

    Disc Medicine

    Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).

    phase 2 small molecule active

    1 trial

  8. R932333

    RIGEL PHARMACEUTICALS INC

    Lupus Erythematosus, Discoid

    phase 2 small molecule completed

    1 trial

  9. RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

    Disc Medicine

    Myelofibrosis

    phase 2 other active

    1 trial

  10. Rybelsus 7 mg tablets, Kerendia 20 mg film-coated tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  11. Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

    Disc Medicine

    Limited metastatic pancreatic cancer

    phase 2 other active

    1 trial

  12. Saphnelo 300 mg concentrate for solution for infusion, Saphnelo placebo

    Disc Medicine

    Sjogren's disease

    phase 2 small molecule active

    1 trial

  13. Sitravatinib, Tislelizumab, Sitravatinib

    Disc Medicine

    Uveal melanoma

    phase 2 small molecule active

    1 trial

  14. Skyrizi 600 mg concentrate for solution for infusion

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  15. Skyrizi 600 mg concentrate for solution for infusion, Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  16. Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion., Cinryze 500 IU powder and solvent for solution for injection

    Disc Medicine

    aneurysmal subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  17. Softisan 378, Cannabidiol

    Disc Medicine

    psychological disorders: PTSD; Anxiety disorders

    phase 2 small molecule active

    1 trial

  18. Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO)

    Disc Medicine

    Primary aldosteronism

    phase 2 other active

    1 trial

  19. TOPIRAMATE

    Disc Medicine

    human immunodeficiency virus 1 (HIV-1)

    phase 2 small molecule active

    1 trial

  20. Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    (Diffuse) Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  21. Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  22. Temozolomide Accord 180 mg hard capsules., Temozolomide Accord 250 mg hard capsules., Temozolomide Accord 5 mg hard capsules., Temozolomide SUN 5 mg hard capsules, Temozolomide Accord 20 mg hard capsules., Temozolomide SUN 180 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide Accord 100 mg hard capsules., Temozolomide SUN 140 mg hard capsules, Temozolomide Accord 140 mg hard capsules., Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 20 mg hard capsules

    Disc Medicine

    Diffuse Midline Glioma, H3K27-altered

    phase 2 small molecule active

    1 trial

  23. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  24. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources